You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 10,071,108

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,071,108

Title:	Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
Abstract:	The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
Inventor(s):	Andre; Patrice (Lyons, FR), Lotteau; Vincent (Lyons, FR), Radreau; Pauline (Lyons, FR), Gilardone; Marine (Millery, FR), Patin; Amaury (Lausanne, CH), Roche; Didier (Ecully, FR), Cravo; Daniel (Montesson, FR), Hallakou-Bozec; Sophie (Antony, FR)
Assignee:	INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE CLAUDE BERNARD--LYON 1 (Villeurbann, FR) ENS--ECOLE NORMALE SUPERIEURE DE LYON (Lyons, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) EDELRIS (Lyons, FR) POXEL (Lyons, FR)
Application Number:	15/898,944
Patent Claims:	1. A method for treating a chronic hepatitis B virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a farnesoid X receptor (FXR) agonist. 2. The method of claim 1, wherein the subject is infected with a hepatitis B virus genotype selected from genotype A, B, C, and D. 3. The method of claim 1, wherein the farnesoid X receptor (FXR) agonist is a selective FXR agonist. 4. The method of claim 1, wherein the farnesoid X receptor (FXR) agonist is selected from the group consisting of the compounds identified by the CAS REGISTRY NUMBERS 1192171-69-9, 6ECDCA, GW4064, PXL0914, and PXL0743. 5. The method of claim 1, wherein the farnesoid X receptor (FXR) agonist is selected from the group consisting of the compounds identified by the CAS REGISTRY NUMBERS 1192171-69-9 and 6ECDCA. 6. The method of claim 1, wherein the subject has failed to respond to a previous treatment for HBV infection. 7. The method of claim 6, wherein the previous treatment is selected from the group consisting of lamivudine (Epivir), adefovir (Hepsera), tenofovir (Viread), telbivudine (Tyzeka), entecavir (Baraclude), interferon alpha-2a, PEGylated interferon alpha-2a (Pegasys) and interferon alpha-2b (ViraferonPeg or Introna). 8. The method of claim 1, wherein the FXR agonist is administered in combination with a treatment selected from the group consisting of lamivudine (Epivir), adefovir (Hepsera), tenofovir (Viread), telbivudine (Tyzeka), entecavir (Baraclude), interferon alpha-2a, PEGylated interferon alpha-2a (Pegasys) and interferon alpha-2b (ViraferonPeg or Introna). 9. A method for reducing synthesis and/or secretion of HBsAg and/or HBeAG or for reducing serum HBV DNA in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a farnesoid X receptor (FXR) agonist. 10. The method of claim 9, wherein the subject is infected with a hepatitis B virus genotype selected from genotype A, B, C, and D. 11. The method of claim 9, wherein the farnesoid X receptor (FXR) agonist is a selective FXR agonist. 12. The method of claim 9, wherein the farnesoid X receptor (FXR) agonist is selected from the group consisting of the compounds identified by the CAS REGISTRY NUMBERS 1192171-69-9, 6ECDCA, GW4064, PXL0914, and PXL0743. 13. The method of claim 9, wherein the farnesoid X receptor (FXR) agonist is selected from the group consisting of the compounds identified by the CAS REGISTRY NUMBERS 1192171-69-9 and 6ECDCA. 14. The method of claim 9, wherein the subject has failed to respond to a previous treatment for HBV infection. 15. The method of claim 14, wherein the previous treatment is selected from the group consisting of lamivudine (Epivir), adefovir (Hepsera), tenofovir (Viread), telbivudine (Tyzeka), entecavir (Baraclude), interferon alpha-2a, PEGylated interferon alpha-2a (Pegasys) and interferon alpha-2b (ViraferonPeg or Introna). 16. The method of claim 9, wherein the FXR agonist is administered in combination with a treatment selected from the group consisting of lamivudine (Epivir), adefovir (Hepsera), tenofovir (Viread), telbivudine (Tyzeka), entecavir (Baraclude), interferon alpha-2a, PEGylated interferon alpha-2a (Pegasys) and interferon alpha-2b (ViraferonPeg or lntrona).

Details for Patent 10,071,108

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	10/16/2002	⤷ Try a Trial	2033-09-11
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	01/07/2004	⤷ Try a Trial	2033-09-11
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	09/29/2011	⤷ Try a Trial	2033-09-11
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.